Ethical pharma producer Takeda

ETHICAL PHARMA

PRODUCER

For over 30 years Takeda Italy has been one of the most important European operations of the Japanese giant, Takeda Pharmaceuticals. Operating under the group principle of ‘Takeda-ism’, the company is dedicated not only to ethical production but also to sustainability and employee welfare, as Industry Europe discovers.

Takeda Pharmaceutical Company Ltd is the biggest pharmaceutical company in Japan. Since its establishment in Osaka in 1781, the company’s strategy has been focused on quality and in particular on a perfect integration between advanced research and the development of human resources.

Takeda’s website outlines the key philosophy behind the group’s approach: “Takeda is committed to striving towards better health for patients worldwide through leading innovation in medicine, in accordance with the principles of our corporate strategy of ‘Takedaism’ – Integrity, Fairness, Honesty and Perseverance.”

In 1982 Takeda Italy was set up. Today the company, which has almost 500 employees and annual net sales of around €400 million, is one of the most important enterprises in Italy in the pharmaceutical sector and provides Takeda’s drugs and service to Italian medical professionals and patients.

Takeda Italy’s production unit is in Cerano, a town in the north of Italy in the province of Novara. This site is highly developed from both a technological and environmental point of view. 130 employees work on the manufacture, control and packaging of some of the most specialised drugs, mainly oral-solid drugs, that are sold by Takeda throughout Europe. Today, the factory manufactures some of the most important products marketed by Takeda affiliates in Europe and some Asian countries as well.

The state-of-the-art production site in Cerano covers 53,000m2 (of which 10,000m2 is covered) and it is equipped with a complex photovoltaic system to reduce its CO2 emissions by many thousands of tonnes each year. It also boasts several highly automated production and packaging lines capable of producing 15,000 units per hour. Areas of operation

Takeda Pharmaceutical Company concentrates most of its resources on the development of new drugs in those areas where the demand is the highest among patients: diabetes, gastroenterology, gynaecology, oncology and cardiology.

In oncology, Takeda has studied the influence of sexual hormones on some cancer pathologies. With the exploitation of an innovative, cutting-edge technology, it succeeded in improving the quality of life of patients affected by prostatic carcinoma, breast cancer and endometriosis.

In gastroenterology, Takeda has developed the most widely used drug in the world for the cure of peptic ulcer and esophagitis. This drug was the solution to a problem that affects 30 per cent of the adult western population.

It is also worth mentioning the discovery of the most advanced class of drugs against hypertension that help reduced blood pressure gradually with the result of decreasing the risk of cardiovascular diseases.

R&D

All the company’s great achievements would not have been possible without an extremely innovative R&D department. Research activities are carried out in compliance with international developmental plans in order to share the knowledge and monitor the use of drugs. Research focuses on the setting up and the management of clinical studies in collaboration with the European Research Centre and with a global coordination that involves Takeda in Japan and the USA.

In particular, the Italian research team works in synergy with national institutions, such as universities and hospitals, and it is mainly formed by specialised doctors who are highly trained researchers.

Committed to responsible growth

Takeda’s commitment to social campaigns and charitable initiatives is witnessed by an impressively long list. For example, its ‘Open Factories’ initiative promoted by Federchimica has given schools, universities, councils and employees’ families the chance to visit companies’ production units and take part in workshops and seminars.

Takeda also funds voluntary associations that are involved in the battle against different pathologies and diseases, such as AISA Onlus (Italian Association against Ataxia), AISW (Williams Syndrome Italian Association).

Finally, sustainability continues to be a major cornerstone of the group’s development. As its website states: “Since 2003, the Takeda Italia plant has established a multi-annual programme wih the objective of reducing CO2 emissions and the consumption of non-renewable energy. Through continuous training, education and investments we have created a culture whereby all our employees pay great attention to environmental preservation.” n

Since 1969 Carlucci has been a leading company in the production of self-adhesive labels, its core business, made using the most advanced technologies.

Its factory covers an area of approx. 10,000 square metres, of which 4000 are covered.

All labels are made using various printing technologies, combined in-line to increase process effi ciency and make control systems more effective.

Printing technologies such as fl exo, letterpress, screen printing, thermal transfer, ink-jet and laser can be combined to ensure end products of the highest quality.

The production process is complemented by 100% inspection and fi nishing operations with variable numbering and control, as well as certifi cation of the numbering.

Carlucci regularly invests in its production processes in order to keep up with technological developments in this market.

The implementation of quality processes is continuously monitored and certifi ed by audits to ensure that the business system effectively complies with ISO standards.

CARLUCCI S.r.l. Unipersonale • Via dei Castelli Romani 44, 00071 Pomezia, Rome, Italy Tel: +39 06 9160021 • Fax: +39 06 9120765 • E-mail: info@carluccietichette.it • www.carluccietichette.it